Trade

with

Discovery Laboratories Inc
(NASDAQ: DSCO)
AdChoices
1.92
+0.04
+2.13%
After Hours :
-
-
-

Open

1.92

Previous Close

1.88

Volume (Avg)

434.25k (335.07k)

Day's Range

1.88-2.01

52Wk Range

1.51-2.77

Market Cap.

163.60M

Dividend Rate ( Yield )

-

Beta

1.66

Shares Outstanding

85.21M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 388.00k

    • Net Income

    • -45.22M

    • Market Cap.

    • 163.60M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -3,660.65

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.66

    • Forward P/E

    • -4.57

    • Price/Sales

    • 113.64

    • Price/Book Value

    • 4.17

    • Price/Cash flow

    • -3.57

      • EBITDA

      • -43.04M

      • Return on Capital %

      • -89.09

      • Return on Equity %

      • -164.40

      • Return on Assets %

      • -89.09

      • Book Value/Share

      • 0.46

      • Shares Outstanding

      • 85.21M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 5.50

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.42

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 500.50

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -39.02

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -61.29

            • 82.75

            • Pre-Tax Margin

            • -3,660.65

            • 39.38

            • Net Profit Margin

            • -3,660.65

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.49

              • 0.76

              • Current Ratio

              • 6.12

              • 2.92

              • Quick Ratio

              • 6.04

              • 2.35

              • Interest Coverage

              • -13.50

              • 38.02

              • Leverage Ratio

              • 1.77

              • 2.21

              • Book Value/Share

              • 0.46

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -3.12

                • 243.90

                • P/E Ratio 5-Year High

                • -25.22

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.33

                • 124.82

                • Price/Sales Ratio

                • 113.64

                • 9.29

                • Price/Book Value

                • 4.19

                • 8.39

                • Price/Cash Flow Ratio

                • -3.57

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -164.40

                    (-369.10)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -89.09

                    (-123.40)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -104.87

                    (-267.00)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 8.47

                  • 1.48

                  • Asset Turnover

                  • 0.02

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -44.51M
                  Operating Margin
                  -11,471.13
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -3.57
                  Ownership

                  Institutional Ownership

                  61.63%

                  Top 10 Institutions

                  51.56%

                  Mutual Fund Ownership

                  21.50%

                  Float

                  85.38%

                  5% / Insider Ownership

                  1.21%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Health Care Portfolio

                  •  

                    3,739,618

                  • 0.19

                  • 4.39

                  • Fidelity® Advisor Small Cap Opps Fund

                  •  

                    3,332,539

                  • 0.00

                  • 3.91

                  • Fidelity® Stock Selector Small Cap Fund

                  •  

                    1,566,863

                  • 0.00

                  • 1.84

                  • Turner Medical Sciences Long/Short

                  •  

                    1,425,423

                  • 89.36

                  • 1.67

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,421,499

                  • 0.00

                  • 1.67

                  • Turner Spectrum Fund

                  •  

                    1,046,097

                  • 59.09

                  • 1.23

                  • Fidelity Advisor® Health Care Fund

                  •  

                    797,500

                  • 0.19

                  • 0.94

                  • Vanguard Extended Market Index Fund

                  •  

                    755,154

                  • 2.92

                  • 0.89

                  • Fidelity® Large Cap Stock Fund

                  •  

                    638,886

                  • 0.49

                  • 0.75

                  • Fidelity VIP Health Care Portfolio

                  •  

                    505,504

                  • 0.14

                  • 0.59

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    12,639,199

                  • +0.41%

                  • 14.83

                  • Broadfin Capital, LLC

                  •  

                    8,066,000

                  • 0.00%

                  • 9.47

                  • Dafna Capital Management LLC

                  •  

                    5,698,739

                  • 0.00%

                  • 6.69

                  • Deerfield Management Co

                  •  

                    3,659,700

                  • 0.00%

                  • 4.29

                  • Baker Bros Advisors LLC

                  •  

                    3,652,117

                  • 0.00%

                  • 4.29

                  • BlackRock Fund Advisors

                  •  

                    2,363,914

                  • +4.65%

                  • 2.77

                  • Wellington Management Company, LLP

                  •  

                    2,144,485

                  • 0.00%

                  • 2.52

                  • Vanguard Group, Inc.

                  •  

                    2,003,276

                  • +0.53%

                  • 2.35

                  • Alyeska Investment Group, L.P.

                  •  

                    1,956,841

                  • +8.13%

                  • 2.30

                  • Millennium Management LLC

                  •  

                    1,750,000

                  • +21.83%

                  • 2.05

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  Discovery Laboratories Inc was incorporated as a Delaware corporation in 1992. The Company is a specialty biotechnology company engaged in creating life-saving products for critical-care patients with respiratory disease and improvin...moreg the standard of care in pulmonary medicine. Its proprietary drug technology produces a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for normal respiratory function and survival. The Company is developing its KL4 surfactant in liquid, lyophilized and aerosolized dosage forms. IT is also developing novel drug delivery technologies potentially to enable efficient delivery of its aerosolized KL4 surfactant. The Company is initially engaged in improvin...moreg the management of respiratory distress syndrome (RDS) in premature infants. It has developed a disposable aerosol-conducting airway connector for infants that is intended to simplify the delivery of aerosolized medications and other inhaled therapies to critical-care patients requiring ventilatory support. The Company has exclusive rights to its CAG technology for use with pulmonary surfactants for all respiratory diseases and conditions. In addition, it hold in the U.S. exclusive rights to the CAG technology for use with certain non-surfactant drugs to treat various pediatric and adult respiratory indications in hospitals and other health care institutions. It has also developed a novel, disposable aerosol-conducting airway connector that is intended to simplify the delivery of aerosolized medications, including its aerosolized KL4 surfactant, and inhaled therapies to infants requiring ventilatory support in the NICU and PICU. AEROSURF, AFECTAIR, AFECTAIR DUO, DISCOVERYLABS, SURFAXIN, SURFAXIN LS, and WARMING CRADLE are the Company’s registered and common law trademarks. The Company’s development, manufacture, distribution, marketing and advertising of drug, device, and combination drug-device products are subject to extensive regulation by federal, state and local governmental authorities in the U.S., including the FDA, and by similar agencies in other countries.lessless

                  Key People

                  John G. Cooper

                  CEO/Director/President

                  John R. Leone

                  Chairman of the Board/Director

                  Mr. John Tattory

                  CFO/Chief Accounting Officer/Senior VP

                  Mr. William C. Roberts

                  Vice President, Divisional

                  Thomas Hoy

                  Vice President, Divisional

                  • Discovery Laboratories Inc

                  • 2600 Kelly Road

                  • Warrington, PA 18976-3622

                  • USA.Map

                  • Phone: +1 215 488-9300

                  • Fax: +1 215 488-9301

                  • discoverylabs.com

                  Incorporated

                  1992

                  Employees

                  126

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: